| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
1-Boc-4-(aminomethyl)piperidine does not have a defined pharmacological target as it is a protected piperidine building block and synthetic intermediate. The compound is a precursor in the preparation of a variety of different protein agonists or antagonists including: kinesin spindle protein inhibitors with potential anticancer activity, orphan G-protein coupled receptor GPR119 agonist with antidiabetic potential, and Pim-1 inhibitors. It is also used in the preparation of orally active platelet-activating factor antagonists.
|
|---|---|
| ln Vitro |
No specific in vitro pharmacological activity data are available for 1-Boc-4-(aminomethyl)piperidine as it is a synthetic intermediate. In research settings, the compound is used as a building block for synthesizing libraries of piperidine-based compounds that are subsequently screened for biological activity. Its activity is assessed in terms of synthetic utility and reactivity rather than direct biological activity. The compound is used in the preparation of protein agonists and antagonists.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for 1-Boc-4-(aminomethyl)piperidine as a therapeutic agent. The compound is used in chemical synthesis and is not administered directly to animals. Its derivatives, including kinesin spindle protein inhibitors and GPR119 agonists, may be evaluated in animal models depending on the therapeutic area.
|
| Enzyme Assay |
For non-cellular assays, 1-Boc-4-(aminomethyl)piperidine is characterized by standard analytical techniques including NMR, HPLC, and mass spectrometry to confirm identity and purity. Purity is typically ≥97%. The compound has a molecular weight of 214.30 and molecular formula C₁₁H₂₂N₂O₂. Boiling point: 237-238°C. Density: 1.013 g/mL at 25°C. Storage: room temperature.
|
| Cell Assay |
For in vitro cell-based studies, 1-Boc-4-(aminomethyl)piperidine is not typically used as a direct test compound. It is a building block for synthesizing biologically active molecules that are subsequently tested in cell-based assays. If handled in a biological laboratory context, standard safety precautions should be taken. The compound should be stored in a cool, dry place protected from light and moisture.
|
| Animal Protocol |
For in vivo animal studies, 1-Boc-4-(aminomethyl)piperidine can be formulated using standard injection vehicles. The compound is a liquid or low melting solid at room temperature. Dosing solutions should be freshly prepared and administered according to specific protocols with appropriate control groups. Standard handling procedures for piperidine derivatives should be followed.
|
| ADME/Pharmacokinetics |
1-Boc-4-(aminomethyl)piperidine has a molecular weight of 214.30 and molecular formula C₁₁H₂₂N₂O₂. It appears as a colorless to yellow liquid or low melting solid with a boiling point of 237-238°C and density of 1.013 g/mL at 25°C. Purity: typically ≥97%. Storage: room temperature.
|
| Toxicity/Toxicokinetics |
1-Boc-4-(aminomethyl)piperidine is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD₅₀ values and detailed toxicological profiles have not been extensively reported.
|
| Additional Infomation |
1-Boc-4-(aminomethyl)piperidine (CAS 144222-22-0) is a precursor in the preparation of a variety of different protein agonists or antagonists including: kinesin spindle protein inhibitors with potential anticancer activity, orphan G-protein coupled receptor GPR119 agonist with antidiabetic potential, and Pim-1 inhibitors. It is also used in the preparation of orally active platelet-activating factor antagonists. The compound aids in compound library expansion and is a reliable choice for developing novel chemical entities in drug discovery efforts. No clinical trials or therapeutic approvals exist.
|
| Molecular Formula |
C11H22N2O2
|
|---|---|
| Molecular Weight |
214.30
|
| Exact Mass |
214.168
|
| CAS # |
144222-22-0
|
| PubChem CID |
736817
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
321.8±15.0 °C at 760 mmHg
|
| Flash Point |
148.4±20.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.458
|
| LogP |
1.59
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
215
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NCC1CCN(C(OC(C)(C)C)=O)CC1
|
| InChi Key |
KLKBCNDBOVRQIJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H22N2O2/c1-11(2,3)15-10(14)13-6-4-9(8-12)5-7-13/h9H,4-8,12H2,1-3H3
|
| Chemical Name |
tert-butyl 4-(aminomethyl)piperidine-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6664 mL | 23.3318 mL | 46.6636 mL | |
| 5 mM | 0.9333 mL | 4.6664 mL | 9.3327 mL | |
| 10 mM | 0.4666 mL | 2.3332 mL | 4.6664 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
